View Total Prescribing Information OPDIVO® (nivolumab) is indicated for your treatment of Grownup patients with classical Hodgkin lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem mobile transplantation (HSCT) and brentuximab vedotin or right after 3 or even more traces of systemic therapy that features autologous